Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

BLADDER CANCER

Novel intravesical gemcitabine delivery system (TAR-200) for neoadjuvant treatment of MIBC: context is everything

Nature Reviews Urology volume 19, pages 579–580 (2022)Cite this article

Subjects

Muscle-invasive bladder cancer (MIBC) remains a deadly disease, despite aggressive surgical and systemic chemotherapeutic treatments. New treatment modalities are needed. A novel intravesicle drug delivery device for neoadjuvant treatment of MIBC has been developed, and preliminary results on the efficacy and safety of this system are available.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Apolo, A. B. et al. Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States. Urol. Oncol. 32, 637–644 (2014).

    Article  Google Scholar 

  2. Daneshmand, S. et al. The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: a phase I trial. Urol. Oncol. https://doi.org/10.1016/j.urolonc.2022.02.009 (2022).

    Article  PubMed  Google Scholar 

  3. Green, D. B. et al. Complications of intravesical BCG immunotherapy for bladder cancer. Radiographics 39, 80–94 (2019).

    Article  Google Scholar 

  4. Pfister, C. et al. Randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin, or gemcitabine and cisplatin as perioperative chemotherapy for patients with muscle-invasive bladder cancer. Analysis of the GETUG/AFU V05 VESPER trial secondary endpoints: chemotherapy toxicity and pathological responses. Eur. Urol. 79, 214–221 (2021).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Brady Urological Institute, Johns Hopkins Medicine, Baltimore, MD, USA

    Katherine M. Rodriguez

  2. The Greenberg Bladder Cancer Institute & James Buchanan Brady Urological Institute, Johns Hopkins Medicine, Baltimore, MD, USA

    Max Kates

Authors
  1. Katherine M. Rodriguez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Max Kates
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Max Kates.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rodriguez, K.M., Kates, M. Novel intravesical gemcitabine delivery system (TAR-200) for neoadjuvant treatment of MIBC: context is everything. Nat Rev Urol 19, 579–580 (2022). https://doi.org/10.1038/s41585-022-00634-w

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41585-022-00634-w

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research